I can't find anywhere in Dr. Yang's paper where he measures

New Post Public Reply Private Reply Replies (2) Message Board
havasu78 ohm20 #79916
642
I can't find anywhere in Dr. Yang's paper where he measures the concentration of leronlimab in his patients, let alone offers any commentary on efficacy vs. blood concentratoin.

The only reference in Dr. Yangs paper as to 45ug/mL that I could find is the following:

"Binding of leronlimab to CCR5 on cells not only blocks HIV-1 entry, but also prevents CCL5-mediated calcium flux with an IC50 of about 45 μg/mL [8] and is therefore a potent inhibitor of CCR5- mediated chemotaxis."

I think Dr. Yang is simply repeating the original PRO140 mouse data from the article cited by midwesthedgie.

Midwesthedgie's tweet has some obvious problems that suggest the guy is clueless. He substitues freely "micrograms" for "milligrams" so whatever numbers he offers in his tweet are obviuosly wrong.

However, the thrust of midwesthedgies argument is more interesting, although it probably does not apply to covid.

Midwesthedge says he is short because the original PRO 140 mouse work, linked by midwesthedgie's tweet, suggests that a blood concentration of 45 micrograms per milliliter is need to get LL to work.

Midwesthedgie goes on to say that measured blood levels of LL in human patients never reach 45 micrograms per milliliter, and that is shown in midwesthedgie's linked article on human LL trials.

Midwesthedgie is right about one thing: Human trial blood levels have never reached 45 micrograms per milliliter.

If you look at the preclinicalLL HIV trial human trial results, subcutaneously injected LL never gets much above 25 micrograms per milliliter. (The plots from the below article max out at 10mg/mL on the 324mg HIV dose, but its very linear so extrapolating 20ug/mL at 700mg dose is reasonable.)

https://academic.oup.com/jid/article/201/10/1...login=true

The inability of subcutaneous LL injection to get above 45 micrograms per milliliter is hardly suprising. If 700mg were injected instantaneously into the average human with 5 liters of blood, the blood concentration would be 140ug/mL. Subcutaneous just cant go in that fast so the peak LL concentration is much lower, around 20-25 mg/mL for a 700mg subcutaneous injection, and the peak is obtained about 48 hours after the injection as shown in other PRO140 HIV human trial data.

So midwesthedgie is right that LL never hits the 45ug/mL level delineated in the original PRO140 mouse experiments and then repeated in Dr. Yang's recent paper.

Unfortunately, the significance of IC50 for calcium channels in mice has never been demonstrated. What's the point? No one knows.

Patterson has demonstrated near 100% CCR5 receptor occupancy at blood concentration levels far below 45ug/mL, although I don't think Patterson measured LL levels in blood.

So what's the deal? Is IC50 for calcuim channel inhibition the critical point or is receptor occupancy the critical point?

LL is certainly working for some covid patients at levels well below 45ugmL.

And LL works for almost all HIV patients at levels well below 45ug/mL.

It would be great if Cytodyn had benn doing some R&D to get a handle on this, but probs going forward they will have an opportunity.

Those PRO140 guys were completely wrong for decades in their often repeated claim that "PRO140 does not effect CCR5 signalling." Completely and totally wrong for decades.

In the podcast, midwesthedgie says, "Leronlimab is a very old asset, 25 years old. The big pharma companies are not stupid, if it was important they would have figured it out."

So that's midwesthedgie's argument, 1) LL never gets to 45ug/mL, and 2) if it was good for anything someone would have figured it out. He throws in there that Cytodyn is "too promotional" and the moderator responds, "Yes, even their name Cytodyn sounds weird."

I think there are some test tube experiment reports that measure some chemotaxis effects as a fuction of LL concentration, but my quick google scholar search was unable to track them down.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Faces Class Action Over Stock Missteps

Updated Category News Views 4

A lawsuit has been lobbed at D-Wave Quantum Inc., and Wall Street's abuzz over it. Investors who've dabbled in NASDAQ:QBTS between February 26 and August 25, 2026 might be eligible to hop onto this class action lawsuit train. The beef is all about allegedly misleading statements concerning the company's operational outlook, and it's a familiar song and dance when a...

Continue Reading
Iranian Cyber Group Shifts Tactics, Hits U.S. Soil

Updated Category News Views 12

A Stealthy Comeback on U.S. Turf In an era where cyber skirmishes aren’t just happening in digital ether but echoing throughout geopolitical landscapes, we have an eye-opener: Prince of Persia, that covert Iranian cyber player, has popped up stateside. Tomer Bar from Semperis has been dogging their trail for years and recently stumbled upon their latest U.S.-based...

Continue Reading
Microtubule Defects Revealed: Impacts on Cancer Treatment

Updated Category News Views 5

Peering into the Heart of Microtubules Ever squint at a tapestry, only to find a rogue thread ruining the pattern? Well, that’s somewhat what scientists at Kanazawa University have found with microtubules, those tiny rods in our cells that usually keep it all together. Using some pretty fancy tech called high-speed atomic force microscopy, these folks peered into the...

Continue Reading
ThreatLocker Launches Global AI Awareness Campaign

Updated Category News Views 2

Kicking Off with Pop Culture Pizzazz Ah, the sweet sound of a campaign that knows how to tug at the heartstrings of nostalgia. ThreatLocker has gotten creative with its latest strategy to get people buzzing about AI safety. They're unleashing a worldwide campaign themed around 'Terminator 2.' Now that's a throwback! If you've ever caught yourself wide-eyed at the edge of...

Continue Reading
Better Home's Litigation Storm: Investor Alert for Stakeholders

Updated Category News Views 2

Legal Murmurs Rock Better Home & Finance Like an old ship caught in a storm, Better Home & Finance Holding Company (NASDAQ: BETR) finds itself teetering on unstable seas. Investors got blindsided by a dramatic 28.5% drop in stock value on May 7, 2026, following revelations from the company's first-quarter earnings call that investors aren't likely to forget anytime soon....

Continue Reading
James Cahill's Centenary: Honoring a Chinese Art Pioneer

Updated Category News Views 4

A Celebration of a Visionary in Chinese Art In the typically bustling city of Hangzhou, a quiet reverence fell at the China Academy of Art (CAA) on October 17–18, 2026. There, they marked the centenary of one of the titans of art history, James Francis Cahill. He was the kind of person who could walk into a room and change how you looked at the walls. His legacy...

Continue Reading
Frost & Sullivan Boosts China Insight with LeadLeo

Updated Category News Views 3

Navigating China's Complex Market Landscape You've got to understand, the stakes in China are like a high-wire act—mystifying and risky, yet bountiful if you play your cards right. Frost & Sullivan's latest maneuver into China's business intel scene is basically the lifeline for navigating this increasingly convoluted market. With China surging ahead in AI, biotech, and...

Continue Reading
Rocket Companies' Earnings Preview: What's at Stake?

Updated Category News Views 2

Anticipation Builds Around Rocket's Earnings Call It ain't every day that a company's earnings announcement stirs up interest the way Rocket Companies' (NYSE:RKT) upcoming third-quarter results have. But here we are, just days away from October 29, 2026, when leadership will lay out the cards at 4:30 p.m. ET. This announcement might just be what investors like us need to...

Continue Reading
Vertice P2P Aims to Transform Procurement Efficiency

Updated Category News Views 9

Vertice Dives Deeper into the Procurement Game Grab a coffee and let's talk some procurement—one of the least sexy, yet utterly essential parts of any operation. Vertice's latest announcement is anything but mundane. They're spiraling deeper into the procurement universe with their new Procure-to-Pay (P2P) capability, a bold expansion from their Intake-to-Procure (I2P)...

Continue Reading
Unpacking the Sonic NEXT S13: A Toolbox Evolution

Updated Category News Views 3

An All-in-One Solution Rolls In Listen up, gearheads and wrench-turners. Sonic Tools USA isn’t messing around with their newest release, the Sonic NEXT S13 toolbox. If you're tired of wrestling stubborn storage or losing track of your tools, this might just be what the shop ordered. Built to endure the tough grind of workshops from aviation to auto repair, the S13 is...

Continue Reading

Top 5 Most Recently Viewed Articles

Eco Wave Power Moves Ahead with Landmark Wave Energy Project

Updated Category News Views 337

Eco Wave Power Secures Final Permit for Wave Project Eco Wave Power Global AB (NASDAQ: WAVE) is thrilled to announce that it has successfully obtained the final Nationwide Permit (NWP) from the U.S. Army Corps of Engineers for its innovative wave energy project. This groundbreaking initiative is set to take place at the Port of Los Angeles, representing a significant leap...

Continue Reading
XOMA Royalty Closes Acquisition of LAVA Therapeutics Shares

Updated Category News Views 176

XOMA Royalty Concludes Acquisition of LAVA Therapeutics In a landmark move, XOMA Royalty Corporation (Nasdaq: XOMA) has announced the completion of its acquisition of LAVA Therapeutics N.V. (NASDAQ: LVTX). This acquisition involved the purchase of all outstanding common shares of LAVA, valued at €0.12 each, with shareholders receiving $1.04 in cash for each share as...

Continue Reading
Medical Displays Market: Unlocking Growth Opportunities Ahead

Updated Category News Views 96

Medical Displays Market Overview The global medical displays market is on an impressive growth trajectory, with a projected valuation estimated to reach US$3.45 billion. This noteworthy surge from US$2.50 billion, which marked the market's value in 2024, is attributed to several key factors. The ongoing rise in chronic diseases, coupled with an aging population and...

Continue Reading
Jim Belushi's Farm Debuts Signature Cannabis Strains

Updated Category News Views 445

Belushi's Farm Introduces Exciting Cannabis Strains Jim Belushi, the acclaimed cannabis advocate and founder of Belushi's Farm, is thrilled to announce a partnership with Wondergrove, enhancing their reach by introducing signature strains across Ohio. This initiative is a part of a broader movement towards sustainable, high-quality cannabis cultivation that emphasizes...

Continue Reading
TRX Gold's Spectacular Year-End Performance Fuels Growth Plans

Updated Category News Views 159

Strong Year-End Results from TRX Gold TRX Gold Corporation (TSX: TRX) has recently shared its impressive fourth quarter results alongside key highlights from the fiscal year ending August 31, 2025. Demonstrating a solid financial performance, the Company achieved remarkable milestones that include record gold production and substantial revenues, setting the stage for an...

Continue Reading